You are here

  • Home
  • Archive
  • Volume 12, Issue 9
  • Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

Citation Tools

Article menu
Oncology
Original research
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
George DJ, Spigel DR, Gordan LN, et al
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
BMJ Open 2022;12:e058396. doi: 10.1136/bmjopen-2021-058396